Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
作者信息
Gomez-Arteaga Alexandra, Margolskee Elizabeth, Wei Mike T, van Besien Koen, Inghirami Giorgio, Horwitz Steven
机构信息
a Department of Medicine , Weill Cornell Medicine/New York Presbyterian Hospital , New York , NY , USA.
b Department of Pathology and Laboratory Medicine , Weill Cornell Medicine/New York Presbyterian Hospital , New York , NY , USA.
出版信息
Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18.
Abstract
摘要
相似文献
1
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.托法替布（泛JAK抑制剂）与鲁索替尼（JAK1/2抑制剂）联合用于治疗伴有JAK3突变的难治性T细胞幼淋巴细胞白血病（T-PLL）。
Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18.
2
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.JAK 抑制剂：治疗银屑病患者的疗效和安全性特征。
J Immunol Res. 2014;2014:283617. doi: 10.1155/2014/283617. Epub 2014 May 5.
3
Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.托法替尼治疗难治性天疱疮：天疱疮的一种可能替代治疗方法。
Dermatol Ther. 2018 Sep;31(5):e12696. doi: 10.1111/dth.12696. Epub 2018 Sep 11.
4
A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy.一例伴有JAK3突变的难治性原发性纵隔B细胞淋巴瘤的独特病例及靶向治疗的作用。
Haematologica. 2014 Sep;99(9):e156-8. doi: 10.3324/haematol.2014.108142. Epub 2014 May 16.
5
Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.JAK 抑制剂对体外和体内巨噬细胞的抗纤维化和抗炎特性：硬皮病相关间质性肺疾病的展望。
Biochem Pharmacol. 2020 Aug;178:114103. doi: 10.1016/j.bcp.2020.114103. Epub 2020 Jun 17.
6
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.使用Janus激酶抑制剂托法替布治疗白癜风时的色素再生可能需要同时暴露于光线下。
J Am Acad Dermatol. 2017 Oct;77(4):675-682.e1. doi: 10.1016/j.jaad.2017.05.043. Epub 2017 Aug 18.
7
Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.携带新型JAK1突变的慢性嗜酸性粒细胞白血病对JAK1/2抑制剂鲁索替尼反应良好。
Blood. 2024 Jul 11;144(2):238. doi: 10.1182/blood.2024024626.
8
Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.托法替布治疗中重度溃疡性结肠炎的真实世界临床疗效。
World J Gastroenterol. 2024 Sep 14;30(34):3929-3931. doi: 10.3748/wjg.v30.i34.3929.
9
The off-label uses profile of tofacitinib in systemic rheumatic diseases.托法替布在全身性风湿性疾病中的超说明书用药情况
Int Immunopharmacol. 2020 Jun;83:106480. doi: 10.1016/j.intimp.2020.106480. Epub 2020 Apr 10.
10
Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.选择性抑制 JAK3 信号传导足以逆转斑秃。
JCI Insight. 2021 Apr 8;6(7):142205. doi: 10.1172/jci.insight.142205.
引用本文的文献
1
Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.双重抑制信号转导和转录激活因子3/信号转导和转录激活因子5作为T-原淋巴细胞白血病的一种新治疗策略
Leukemia. 2025 Apr 15. doi: 10.1038/s41375-025-02577-8.
2
T-cell prolymphocytic leukemia, a case report and review of the literature.T细胞幼淋巴细胞白血病：一例报告并文献复习
Oncol Res. 2025 Feb 28;33(3):505-517. doi: 10.32604/or.2025.058175. eCollection 2025.
3
Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma.皮肤T细胞淋巴瘤中Janus激酶/信号转导及转录激活因子通路的治疗靶向作用
Cancers (Basel). 2025 Feb 7;17(4):568. doi: 10.3390/cancers17040568.
4
Stigmasterol Attenuates Triple-negative Breast Cancer Stem Cell Properties by Inhibiting JAK3.豆甾醇通过抑制JAK3减轻三阴性乳腺癌干细胞特性。
J Cancer. 2025 Feb 3;16(5):1618-1630. doi: 10.7150/jca.94822. eCollection 2025.
5
Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.复发性儿童T细胞急性淋巴细胞白血病和淋巴细胞淋巴瘤。
Haematologica. 2025 Sep 1;110(9):1934-1950. doi: 10.3324/haematol.2024.285643. Epub 2025 Jan 9.
6
Methotrexate, Hydrocortisone, Vincristine, Sobuzoxane, and Etoposide Is an Effective Option for Relapsed T-cell Prolymphocytic Leukemia with Loss of CD52 Expression after Retreatment with Alemtuzumab.甲氨蝶呤、氢化可的松、长春新碱、梭布佐生和依托泊苷是阿仑单抗再治疗后复发的CD52表达缺失的T细胞幼淋巴细胞白血病的有效治疗选择。
JMA J. 2024 Oct 15;7(4):642-645. doi: 10.31662/jmaj.2024-0145. Epub 2024 Sep 27.
7
Prolymphocytic Leukaemia: an Update on Biology and Treatment.慢性淋巴细胞白血病：生物学和治疗的最新进展。
Curr Oncol Rep. 2024 Feb;26(2):129-135. doi: 10.1007/s11912-023-01485-3. Epub 2024 Jan 2.
8
T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.T 细胞前淋巴细胞白血病：诊断、发病机制与治疗。
Int J Mol Sci. 2023 Jul 28;24(15):12106. doi: 10.3390/ijms241512106.
9
Ruxolitinib is effective in the treatment of a patient with refractory T-ALL.芦可替尼对一名难治性T细胞急性淋巴细胞白血病患者的治疗有效。
EJHaem. 2020 Dec 4;2(1):139-142. doi: 10.1002/jha2.143. eCollection 2021 Feb.
10
Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.T 细胞幼淋巴细胞白血病细胞疗法的进展
Front Oncol. 2022 Feb 11;12:781479. doi: 10.3389/fonc.2022.781479. eCollection 2022.
本文引用的文献
1
Genomic Profiling of T-Cell Neoplasms Reveals Frequent and Mutations With Clonal Evasion From Targeted Therapies.T细胞肿瘤的基因组分析揭示了频繁的突变以及对靶向治疗的克隆逃避。
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00019. Epub 2018 Feb 13.
2
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.用于治疗炎症性和肿瘤性疾病的 Janus 激酶（JAK）抑制剂
Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26.
3
Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.T细胞幼淋巴细胞白血病的基因特征揭示了两个主要生物学亚组以及JAK3突变作为预后标志物。
Genes Chromosomes Cancer. 2016 Jan;55(1):82-94. doi: 10.1002/gcc.22313. Epub 2015 Oct 23.
4
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.靶向JAK激酶治疗血液系统恶性肿瘤：从基因改变的识别到临床应用的曲折之路
Haematologica. 2015 Oct;100(10):1240-53. doi: 10.3324/haematol.2015.132142.
5
Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.共同的 JAK1 和 JAK3 突变体能增加对 JAK 抑制剂的耐药性。
Blood. 2014 Dec 18;124(26):3924-31. doi: 10.1182/blood-2014-05-576652. Epub 2014 Oct 28.
6
JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.JAK3 突变通过激活 JAK1 来转化造血细胞，导致小鼠模型中的 T 细胞急性淋巴细胞白血病。
Blood. 2014 Nov 13;124(20):3092-100. doi: 10.1182/blood-2014-04-566687. Epub 2014 Sep 5.
7
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.综合基因组测序揭示T细胞原淋巴细胞白血病的突变图谱。
Blood. 2014 Aug 28;124(9):1460-72. doi: 10.1182/blood-2014-03-559542. Epub 2014 May 13.
8
Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells.Jak2在成体造血干细胞的维持和功能中的关键作用。
Stem Cells. 2014 Jul;32(7):1878-89. doi: 10.1002/stem.1711.
9
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.T 细胞幼淋巴细胞白血病中 JAK3 的复发性突变。
Genes Chromosomes Cancer. 2014 Apr;53(4):309-16. doi: 10.1002/gcc.22141. Epub 2014 Jan 21.
10
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.芦可替尼和托法替布在体外是HIV-1复制和病毒再激活的强效和选择性抑制剂。
Antimicrob Agents Chemother. 2014;58(4):1977-86. doi: 10.1128/AAC.02496-13. Epub 2014 Jan 13.
Zotero 插件